Is tiotropium bromide and olodaterol inhalation spray on the market?

The U.S. Food and Drug Administration (FDA) has approved tiotropium bromide and olodaterol inhalation spray (STIOLTO RESPIMAT) for a broader indication and a new label for the treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Tiotropium bromide and olodaterol inhalation spray were previously approved in in 2015 for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Data show tiotropium bromide may reduce exacerbations of chronic obstructive pulmonary disease.

Exacerbations are a serious complication of COPD that can further damage the lungs and make management of the disease more difficult. The double-blind DYNAGITO trial included 7,880 patients with COPD and a history of exacerbations. Participants were randomized to receive tiotropium bromide olodaterol inhalation spray 5 μg–5 μg or tiotropium bromide 5 μg once daily. The study found that the incidence of acute exacerbations of moderate to severe COPD was lower, but did not reach the target level of significance.

The original drug of tiotropium bromide and olodaterol inhalation spray has been launched in China. The specification (2.5mcg+2.5mcg)*60 sprays per box is about RMB 800. This drug may be sold in domestic hospitals or pharmacies. The original drug of tiotropium bromide and olodaterol inhalation spray has also been launched overseas. The Turkish version's specifications (2.5mcg+2.5mcg) * 60 sprays are priced at about 200 yuan per box (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same. There are currently no generic versions of tiotropium bromide and olodaterol inhalation spray available on the market.